NASDAQ : YDES
YD Bio Limited — Key statistics
Healthcare · Biotechnology · Taiwan
Last price 5.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 420.74M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 420.74M |
| Enterprise Value | 418.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 70.83M |
| Shares Outstanding | 70.83M |
| Shares Change (YoY) | -13.49% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 76.79% |
| Owned by Institutions (%) | 0.46% |
| Float | 16.19M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 1,355.55 |
| Forward PE | n/a |
| PS Ratio | 339.49 |
| Forward PS | n/a |
| PB Ratio | 94.06 |
| P/TBV Ratio | 210.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 1,367.34 |
| EV / Sales | 337.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.23 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -360.63% |
| Return on Capital Employed (ROCE) | -72.88% |
| Weighted Average Cost of Capital (WACC) | 3.56% |
| Revenue Per Employee | $88,522 |
| Profits Per Employee | $21,840 |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -24 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.13 |
| 52-Week Price Change | -55.14% |
| 50-Day Moving Average | 5.12 |
| 200-Day Moving Average | 5.52 |
| Relative Strength Index (RSI) | 52.33 |
| Average Volume (20 Days) | 141,669 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 192,222 |
| Short Previous Month | 177,332 |
| Short % of Shares Out | 0.27% |
| Short % of Float | 1.19% |
| Short Ratio (days to cover) | 0.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.24M |
| Gross Profit | 366,845 |
| Operating Income | -6.55M |
| Pretax Income | 305,738 |
| Net Income | 305,762 |
| EBITDA | -6.34M |
| EBIT | -6.55M |
| Earnings Per Share (EPS) | $0.00 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.66M |
| Total Debt | 5,002 |
| Net Cash | 2.66M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 4.47M |
| Book Value Per Share | 0.06 |
| Working Capital | 4.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.26M |
| Capital Expenditures | -1.45M |
| Depreciation & Amortization | 210,600 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.70M |
| FCF Per Share | -$0.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | 29.60% |
| Operating Margin | -528.72% |
| Pretax Margin | 24.67% |
| Profit Margin | 24.67% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 13.49% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.07% |
| FCF Yield | -2.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 67.4 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |